Pharmacoequity for Older Adults With Inflammatory Bowel Diseases

“Nothing’s worked, and I’m losing my life,” said the tired 73-year-old retired accountant who presented for a second opinion on the treatment of his ulcerative colitis (UC). Three years ago, he developed rectal bleeding and was diagnosed with UC. He did not have a sustained clinical response to mesalamine, vedolizumab, or infliximab, and remained on varying doses of prednisone for 2 years. His wife chimed in that they had intended to spend their retirement traveling, but he cannot even leave the house to go to the grocery store because he is so limited by his bowel movement frequency a nd urgency.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Diversity, Equity, and Inclusion in GI Source Type: research